NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Janssen Pharmaceutical K.K.